Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PED (Fluid-8)

16 novembre 2026 aggiornato da: Honghua Yu,MD

Observation on the Efficacy of Aflibercept 8mg Intravitreal Injection Solution on Retinal Fluid in nAMD Patients With PED: a Multicenter, Prospective Study

Primary Objective: To describe the changes in macular fluid within 12 months in patients with neovascular agerelated macular degeneration (nAMD) complicated by pigment epithelial detachment (PED) receiving 8mg aflibercept treatandextend (T&E) therapy.Secondary Objectives:(1) To explore the correlation between changes in macular fluid (e.g., fluctuation index [FI], volume change, etc.) and visual acuity improvement;(2) To evaluate the associations of macular fluid changes (e.g., fluctuation index [FI], volume change, etc.) and different types of fluid components with alterations in retinal and choroidal structures (e.g., disruption of the ellipsoid zone, thickness of each retinal layer, choroidal thickness, microstructural parameters on OCT and OCTA, etc.);(3) To assess the safety of 8mg aflibercept injections in nAMD patients with PED (e.g., incidence rates of retinal pigment epithelium (RPE) tear, elevated intraocular pressure, endophthalmitis and thromboembolic events).

  1. Study Design (1) Type: Prospective, single-arm, open-label, multicenter study. (2) Sample size: The sample size was calculated based on the Fluid Index (FI) with reference to the results of the TOWER study. The TOWER study described the 24-month macular fluid fluctuation after intravitreal anti-VEGF therapy (bevacizumab, ranibizumab and 2 mg aflibercept) for nAMD in the real-world setting. This study hypothesizes that 8 mg aflibercept is non-inferior to the above three agents in controlling fluid fluctuation. Based on the TOWER study, the assumed mean FI at Month 12 is 42.9 with an SD of 9.8; a sample size of 38 yields a two-sided 95% confidence interval with a half-width of 3.22. Assuming a 20% dropout rate, the minimum number of patients required to reach the primary endpoint is 48. (3) Rationale for indication: The study population consists of patients with nAMD, for which aflibercept is a first-line treatment. The intervention is intravitreal injection of 8 mg aflibercept, whose efficacy and safety have been demonstrated in previous Phase III clinical trials. The T&E regimen is a globally recognized optimized treatment strategy that reduces the treatment burden on patients and healthcare facilities while maintaining sustained disease control.
  2. Study Procedures This study includes a 3-week screening period to assess subject eligibility, followed by a 48-week treatment period. Subjects who provide consent, meet all inclusion criteria and do not meet any exclusion criteria will receive intravitreal injection of 8 mg aflibercept in the study eye. Referencing the ALTAIR study, this study adopts the T&E (treat-and-extend) regimen: one intravitreal injection is administered at Week 0, Week 4 and Week 8 during the loading phase, and the maintenance phase starts at Week 20. During the maintenance phase, all decisions to extend, maintain or shorten the dosing interval are made according to the T&E criteria. The treatment interval should be shortened if any of the following occurs: new fluid (across all tomographic scans), no improvement or worsening of pre-existing fluid, a loss of ≥5 letters in visual acuity compared with the last visit, an increase of ≥100 μm in CRT in the central 1 mm subfield relative to the previous minimum value, or new neovascularization / new submacular hemorrhage. If the criteria for interval shortening are not met, the current interval will be maintained if fluid persists but shows a continuous decreasing trend; the injection interval may be extended as appropriate if there is no active fluid on OCT. In principle, the injection interval is adjusted within the range of 8-24 weeks, with a default adjustment step of 4 weeks each time.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

48

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

50 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 1: (1) Age ≥ 50 years old;

    2: (2) Patients with newlydiagnosed or preexisting nAMD and OCTconfirmed PED;

    3: (3) Patients who are planned to initiate intravitreal injection of aflibercept 8 mg;

    4: (4) Patients voluntarily participate in this study, sign a written informed consent form and are willing to cooperate with followup visits;

    5: (5) Patients are assessed by the investigator to have good compliance;

    6: (6) If both eyes meet the enrollment criteria, the study eye shall be selected according to the following rules: ① When the bestcorrected visual acuity (BCVA) of the two eyes is different, the eye with poorer visual acuity shall be selected; ② When the BCVA of the two eyes is the same, the right eye shall be selected by default.

Exclusion Criteria:

  • 1: (1) Insufficient quality of OCT images, which prevents reliable assessment of Central Retinal Thickness (CST) or Ellipsoid Zone (EZ);

    2: (2) Complete absence of the central EZ at baseline, making it impossible to evaluate its changes during followup;

    3: (3) Coexistence of other macular diseases that may interfere with the evaluation of macular structure (e.g., Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), etc.);

    4: (4) Any condition that may affect patient compliance or scheduled followup (e.g., severe mental disorders, cognitive impairment, substance abuse or addiction, etc.);

    5: (5) Participation in any other clinical research project, or having taken part in any drug clinical trial within 6 months prior to screening examinations;

    6: (6) Presence of any contraindications listed in the prescribing information for Aflibercept 8 mg;

    7: (7) Extraocular/periorbital or intraocular infection or inflammation in either eye at the time of the first study drug injection;

    8: (8) The fellow eye is receiving other intravitreal treatments other than Aflibercept;

    9: (9) The study eye has received intravitreal antiVEGF injections within the past 3 months, intravitreal glucocorticoid therapy within the past 3 months, or a dexamethasone intravitreal implant within the past 6 months;

    10: (10) The patient has a history of immunodeficiency diseases (e.g., HIV, etc.), cancer or malignant tumors, autoimmune diseases, severe cardiovascular or cerebrovascular diseases, or other illnesses that may significantly reduce life expectancy;

    11: (11) Pregnant or lactating women, or women of childbearing potential who are unwilling or unable to use effective contraceptive measures;

    12: (12) Known hypersensitivity to any ingredients contained in the study drug;

    13: (13) Patients deemed unsuitable for participation in this study by the investigator.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Altro: Aflibercept 8mg

Intravitreal Injection of Aflibercept 8 mg

Intravitreal Injection of Aflibercept 8 mg

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fluctuation Index
Lasso di tempo: Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

Parameter source: OCTcentral 1mm CST, including foveal retinal thickness and volume.Calculation formula: FI = Sum of absolute changes in CST between all adjacent visits from baseline to M12 ÷ Number of adjacent intervals.

Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
BCVA
Lasso di tempo: Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

After wearing corrective lenses, outcomes from the ETDRS 4-meter standard protocol or clinical results shall be uniformly converted to ETDRS letter scores; the same method, lighting and distance shall be maintained for the same subject throughout follow-up assessments.

Day 1, Month 1, Month 2, Week 20, and through Month 12 (T&E phase)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

30 settembre 2028

Completamento dello studio (Stimato)

30 settembre 2028

Date di iscrizione allo studio

Primo inviato

4 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • MR-44-26-077408

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .